RAPT Therapeutics, Inc. Common Stock
RAPT Real Time Price USDRecent trades of RAPT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RAPT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Chemokine receptor modulators and uses thereof Sep. 24, 2024
-
Patent Title: Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof Jun. 11, 2024
-
Patent Title: Pyrazole pyrimidine compounds and uses thereof Mar. 05, 2024
-
Patent Title: Anticancer agents Aug. 22, 2023
-
Patent Title: Chemokine receptor modulators and uses thereof Jul. 12, 2022
-
Patent Title: Chemokine receptor modulators and uses thereof Dec. 07, 2021
-
Patent Title: Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof Aug. 10, 2021
-
Patent Title: Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses Jun. 29, 2021
-
Patent Title: Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof Jul. 28, 2020
-
Patent Title: Chemokine receptor modulators and uses thereof Jun. 16, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RAPT in WallStreetBets Daily Discussion
Recent insights relating to RAPT
Recent picks made for RAPT stock on CNBC
ETFs with the largest estimated holdings in RAPT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RAPT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.